Riding the Trend or Protecting Profits: Seattle Genetics, Inc. (SGEN) – The News Heater

Seattle Genetics, Inc. (NASDAQ:SGEN) went down by -1.74% from its latest closing price when compared to the 1-year high value of $124.32 and move down -11.12%, while SGEN stocks collected -3.55% of loss with the last five trading sessions. Press Release reported 15 hours ago that Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40(th) Annual Healthcare Conference

Seattle Genetics, Inc. (NASDAQ: SGEN) The 36 Months beta value for SGEN stocks is at 1.80, while of the analysts out of 0 who provided ratings for Seattle Genetics, Inc. stocks as a buy while as overweight, rated it as hold and as sell. The average price we get from analysts is $127.80 which is $13.87 above current price. SGEN currently has a short float of 2.91% and public float of 170.23 M with average trading volume of 1.10M shares.

SGEN stocks went down by -3.55% for the week, with the monthly jump of 1.83% and a quarterly performance of -7.55%, while its annual performance rate touched 49.81%. The simple moving average for the period of the last 20 days is -3.12% for SGEN stocks with the simple moving average of 22.98% for the last 200 days.

Many brokerage firms have already submitted their reports for SGEN stocks, with Barclays repeating the rating for SGEN shares by setting it to Equal Weight. The predicted price for SGEN socks in the upcoming period according to Barclays is $124 based on the research report published on February 18, 2020.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see SGEN stock at the price of $150, previously predicting the value of $140. The rating they have provided for SGEN stocks is Buy according to the report published on February 12, 2020.

Goldman gave Buy rating to SGEN stocks, setting the target price at $165 in the report published on February 11, 2020.

After a stumble in the market that brought SGEN to its low price for the period of the last 52 weeks, Seattle Genetics, Inc. was unable to take a rebound, for now settling with -10.01% of loss for the given period.

The stock volatility was left at 4.45%, however, within the period of a single month, the volatility rate increased by 7.09%, while the shares surge at the distance of +3.22% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -1.17% lower at the present time.

In the course of the last 5 trading sessions, SGEN went down by -3.55%, which changed the moving average for the period of 200 days to the total of +74.84% of gains for the stock in comparison to the 20-day moving average settled at $115.65. In addition, Seattle Genetics, Inc. saw -2.08% in overturn over the period of a single year with a tendency to cut further losses.

Reports are indicating that there were more than several insider trading activities at Seattle Genetics, Inc. (SGEN), starting from DANSEY ROGER D, who sold 350 shares at the price of $116.33 back on Feb 18. After this action, Rushing now owns 107,659 shares of Seattle Genetics, Inc., valued at $40,716 with the latest closing price.

SIEGALL CLAY B, the President and CEO of Seattle Genetics, Inc., sold 28,472 shares at the value of $114.61 during a trade that took place back on Feb 10, which means that SIEGALL CLAY B is holding 758,784 shares at the value of $3,263,110 based on the most recent closing price.

The current profitability levels are settled at -24.06 for the present operating margin and +95.21 for gross margin. The net margin for Seattle Genetics, Inc. stands at -17.31. Total capital return value is set at -13.67, while invested capital returns managed to touch -9.86. Equity return holds the value -10.20%, with -8.50% for asset returns.

Based on Seattle Genetics, Inc. (SGEN), the companys capital structure generated 4.11 points for debt to equity in total, while total debt to capital is set at the value of 3.94.

The value for Enterprise to Sales is 21.39 with debt to enterprise value settled at 0.00. The receivables turnover for Seattle Genetics, Inc. is 4.80 with the total asset turnover at the value of 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.54.

See the article here:
Riding the Trend or Protecting Profits: Seattle Genetics, Inc. (SGEN) - The News Heater

Related Posts